These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2713961)

  • 21. Acetylator phenotyping: the effect of ethanol on the dapsone test.
    Hutchings A; Monie RD; Spragg B; Routledge PA
    Br J Clin Pharmacol; 1984 Jul; 18(1):98-100. PubMed ID: 6743494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxidative activation of proguanil and dapsone acetylation in Thai soldiers.
    Edstein MD; Shanks GD; Teja-Isavadharm P; Rieckmann KH; Webster HK
    Br J Clin Pharmacol; 1994 Jan; 37(1):67-70. PubMed ID: 8148220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man.
    Edstein MD; Rieckmann KH; Veenendaal JR
    Br J Clin Pharmacol; 1990 Aug; 30(2):259-65. PubMed ID: 2206787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dapsone acetylation in man: another example of polymorphic acetylation.
    Peters JH; Levy L
    Ann N Y Acad Sci; 1971 Jul; 179():660-6. PubMed ID: 5285396
    [No Abstract]   [Full Text] [Related]  

  • 25. The polymorphic acetylation of dapsone in man.
    Gelber R; Peters JH; Gordon GR; Glazko AJ; Levy L
    Clin Pharmacol Ther; 1971; 12(2):225-38. PubMed ID: 5554939
    [No Abstract]   [Full Text] [Related]  

  • 26. Dapsone acetylation in dermatitis herpetiformis.
    Ellard GA; Gammon PT; Savin JA; Tan RS
    Br J Dermatol; 1974 Apr; 90(4):441-4. PubMed ID: 4823883
    [No Abstract]   [Full Text] [Related]  

  • 27. Acedapsone treatment of leprosy patients: response versus drug disposition.
    Peters JH; Murray JF; Gordon GR; Levy L; Russell DA; Scott GC; Vincin DR; Shepard CC
    Am J Trop Med Hyg; 1977 Jan; 26(1):127-36. PubMed ID: 842774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine.
    Ahmad RA; Rogers HJ
    Br J Clin Pharmacol; 1980 Nov; 10(5):519-24. PubMed ID: 7437265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Armadillo as a model for studying chemotherapy of leprosy: preliminary studies.
    Dhople AM
    Indian J Lepr; 1986; 58(1):19-28. PubMed ID: 3745995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute dapsone poisoning: clinical features and pharmacokinetic studies.
    Woodhouse KW; Henderson DB; Charlton B; Peaston RT; Rawlins MD
    Hum Toxicol; 1983 Jul; 2(3):507-10. PubMed ID: 6885095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acetylation and oxidation phenotypes in malignant lymphoma.
    Philip PA; Rogers HJ; Harper PG
    Cancer Chemother Pharmacol; 1987; 20(3):235-8. PubMed ID: 3677298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of acetylator phenotype of the leprosy patient on the emergence of dapsone resistant leprosy.
    Raj PP; Aschhoff M; Lilly L; Balakrishnan S
    Indian J Lepr; 1988 Jul; 60(3):400-6. PubMed ID: 3058828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.
    Horai Y; Fujita K; Ishizaki T
    Eur J Clin Pharmacol; 1989; 37(6):581-7. PubMed ID: 2612554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-acetyltransferase polymorphism in patients with Behçet's disease.
    Aynacioglu AS; Bozkurt A; Nacak M; Kortunay S; Tunc R; Dincel A; Kayaalp SO
    Eur J Clin Pharmacol; 2001 Nov; 57(9):659-62. PubMed ID: 11791896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acetylator phenotype and the effect of dapsone in rheumatoid arthritis.
    Crook PR; Hortas C; Roberts EJ; Swinson DR; Mucklow JC; Shadforth MF
    J Rheumatol; 1983 Oct; 10(5):805-8. PubMed ID: 6644705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood DDS levels and acetylation rates of sulphadimidine in leprosy patients.
    Balakrishnan S; Ramu G
    Lepr India; 1977 Jan; 49(1):59-64. PubMed ID: 330945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors.
    Bluhm RE; Adedoyin A; McCarver DG; Branch RA
    Clin Pharmacol Ther; 1999 Jun; 65(6):598-605. PubMed ID: 10391665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The disposition of dapsone in cirrhosis.
    May DG; Arns PA; Richards WO; Porter J; Ryder D; Fleming CM; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1992 Jun; 51(6):689-700. PubMed ID: 1611807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.
    Carr K; Oates JA; Nies AS; Woosley RL
    Br J Clin Pharmacol; 1978 Nov; 6(5):421-7. PubMed ID: 728285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of dapsone.
    Zuidema J; Hilbers-Modderman ES; Merkus FW
    Clin Pharmacokinet; 1986; 11(4):299-315. PubMed ID: 3530584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.